ID   TCO-2
AC   CVCL_3630
DR   CLO; CLO_0050920
DR   BioSample; SAMN03472216
DR   Cosmic; 877476
DR   Cosmic; 1152550
DR   RCB; RCB0689
DR   Wikidata; Q54971892
RX   PubMed=1607768;
RX   PubMed=24403450;
CC   Population: Japanese.
CC   Doubling time: 93 hours (PubMed=1607768); 69 hours (PubMed=24403450).
CC   Derived from site: In situ; Uterus, cervix; UBERON=UBERON_0000002.
ST   Source(s): RCB=RCB0689
ST   Amelogenin: X
ST   CSF1PO: 9
ST   D13S317: 9,12
ST   D16S539: 10
ST   D5S818: 11,12
ST   D7S820: 11
ST   TH01: 6,9
ST   TPOX: 8
ST   vWA: 18,19,20
DI   NCIt; C4029; Cervical adenocarcinoma
DI   ORDO; Orphanet_213772; Adenocarcinoma of the cervix uteri
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   34Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-09-24; Version: 17
//
RX   PubMed=1607768;
RA   Fushiki, Hiroshi
RT   "Characterization of two novel cell lines established from a single
RT   human uterine cervical adenocarcinoma, and their chemosensitivities
RT   and hormonal effects on their proliferation.";
RL   Nihon Sanka Fujinka Gakkai Zasshi 44:397-404(1992).
//
RX   PubMed=24403450;
RA   Torii, Yutaka
RA   Kato, Rina
RA   Minami, Yukito
RA   Hasegawa, Kiyoshi
RA   Fujii, Takuma
RA   Udagawa, Yasuhiro
RT   "ERCC1 expression and chemosensitivity in uterine cervical
RT   adenocarcinoma cells.";
RL   Anticancer Res. 34:107-115(2014).
//